Knight Therapeutics Inc. is making waves in the market with a notable gain.
Knight Therapeutics Inc. (GUD.TO) is experiencing a significant rise in its stock price, currently up by 4.43% to CA$9.67. This positive movement reflects investor confidence and anticipation ahead of its upcoming financial results.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$957.76M
P/E
65.0x
52W high
$10.17
52W low
$5.66
1W change
-0.61%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 14.6% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+14.6% Upside
Current Price
C$9.76
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
32.3%
Annualized
90-Day Vol
32.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.67
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$10.36 | C$9.27 โ C$11.58 |
| 60 trading days | C$10.99 | C$9.39 โ C$12.87 |
| 90 trading days | C$11.67 | C$9.62 โ C$14.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent surge in Knight Therapeutics' stock price suggests a bullish sentiment among investors, likely driven by upcoming earnings expectations and overall market conditions.
Stock up 4.43% to CA$9.67
Advertisement
Knight Therapeutics' market capitalization stands at approximately CA$917 million, indicating substantial investor interest and market confidence.
Bull case
Investors are feeling optimistic about Knight Therapeutics' growth potential, especially with the upcoming release of its second quarter 2026 results. These results could showcase strong performance and strategic advancements that excite the market.
Bear case
Even with the current upward trend, Knight Therapeutics faces challenges in a competitive pharmaceutical landscape. If the upcoming earnings call reveals disappointing results, it could quickly dampen investor sentiment.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
